NasdaqGS - Delayed Quote • USD
Allogene Therapeutics, Inc. (ALLO)
At close: May 17 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 17 | 16 |
| Avg. Estimate | -0.37 | -0.38 | -1.61 | -1.65 |
| Low Estimate | -0.54 | -0.49 | -2.06 | -2.16 |
| High Estimate | -0.28 | -0.26 | -1.19 | -1.32 |
| Year Ago EPS | -0.53 | -0.37 | -2.09 | -1.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 12 | 15 | 13 |
| Avg. Estimate | 10k | 10k | 50k | 4.71M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 50k | 50k | 200k | 60.97M |
| Year Ago Sales | 44k | -- | 95k | 50k |
| Sales Growth (year/est) | -77.30% | -- | -47.40% | 9,320.00% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.59 | -0.52 | -0.45 | -0.41 |
| EPS Actual | -0.53 | -0.37 | -0.51 | -0.38 |
| Difference | 0.06 | 0.15 | -0.06 | 0.03 |
| Surprise % | 10.20% | 28.80% | -13.30% | 7.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.38 | -1.61 | -1.65 |
| 7 Days Ago | -0.4 | -0.39 | -1.68 | -1.57 |
| 30 Days Ago | -0.4 | -0.39 | -1.65 | -1.57 |
| 60 Days Ago | -0.4 | -0.4 | -1.69 | -1.62 |
| 90 Days Ago | -0.42 | -0.42 | -1.76 | -1.83 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 9 | 8 | 10 | 5 |
| Up Last 30 Days | 9 | 8 | 10 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 2 | 1 | 4 |
Growth Estimates
| CURRENCY IN USD | ALLO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 30.20% | -- | -- | 8.00% |
| Next Qtr. | -2.70% | -- | -- | 12.40% |
| Current Year | 23.00% | -- | -- | 5.60% |
| Next Year | -2.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 1.00% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/16/2024 |
| Maintains | Truist Securities: Buy to Buy | 5/15/2024 |
| Maintains | Stifel: Hold to Hold | 5/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 3/15/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/27/2024 |
Related Tickers
ARQT Arcutis Biotherapeutics, Inc.
9.18
+0.66%
AUTL Autolus Therapeutics plc
4.3900
+7.86%
ATRA Atara Biotherapeutics, Inc.
0.6100
+1.06%
FATE Fate Therapeutics, Inc.
3.9000
-5.80%
CRBU Caribou Biosciences, Inc.
3.3900
-5.57%
MGNX MacroGenics, Inc.
4.3650
-14.75%
VERV Verve Therapeutics, Inc.
5.97
-6.50%
BLUE bluebird bio, Inc.
1.0300
-1.90%
VYGR Voyager Therapeutics, Inc.
8.43
-2.32%
ERAS Erasca, Inc.
1.9700
+6.49%